InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.62
(
-0.20%
)
Bitcoin
65,101.53
(
-0.06%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

iwfal

Send PM Follow Ignore
Followers 75
Posts 4668
Boards Moderated 0
Alias Born 09/06/2003

iwfal

Member Level

Re: iwfal post# 135483

Sunday, 02/12/2012 1:53:48 AM

Sunday, February 12, 2012 1:53:48 AM

Post# of 252254
CLDX -

If I remember from looking earlier in the day, the median number of preceding treatments for the Eribulan P3 was 4. For the CDX-011 BC trial it is a remarkable 7. I'd expect that to have a meaningful effect on background rate of ORR.



A calibration of the difference between the ORR for a drug in refractory and first line:

Tarceva

a) in refractory NSCLC - 13.5% (7/52)
b) in first line NSCLC - 22.7% (12/53)

http://theoncologist.alphamedpress.org/content/12/7/840.full


Looking for monotherapy differences in ORR between 3rd line and 1st line and hard to find. FWIW.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up